Delving into the Latest Updates on NT-301(Nano PharmaSolutions) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NT-301(Nano PharmaSolutions)

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Nano PharmaSolutions, Inc.

Active Organization

Nano PharmaSolutions, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this research project is to investigate the safety and tolerability of an approved drug (Apomorphine) when administered as a nasal powder spray formulation (NT-301) as well as collect information on how NT-301 moves into, through and out of your body, called Pharmacokinetics. The study also aims to compare the safety, tolerability and pharmacokinetics of NT-301 to an injectable Apomorphine product (Movapo Pen), already approved for use in Australia.

Start Date20 Jun 2025

Sponsor / Collaborator

Nano PharmaSolutions, Inc.

[+1]

100 Clinical Results associated with NT-301(Nano PharmaSolutions)

Login to view more data

100 Translational Medicine associated with NT-301(Nano PharmaSolutions)

Login to view more data

100 Patents (Medical) associated with NT-301(Nano PharmaSolutions)

Login to view more data

100 Deals associated with NT-301(Nano PharmaSolutions)

Login to view more data